ARCHIVES

MOPP Consequences, Including Increase In cure Rate, Describe By DeVita

This article is from The Cancer Letter archive.

Vol. 05 No. 21 | May 25, 1979

Download PDF Visit The Full Archive

Related Articles

Biostatistician Thomas Fleming Warns Against Approval of Provenge.

May 4, 2007

DCT Board Okays Extension Of Phase 1 Master Agreements, Increase To $4 Million

February 27, 1987

ACS Asks Higher NCI Authorization

March 24, 1978

Drugs and Targets: Akynzeo approved for chemotherapy-related nausea

October 10, 2014

NCI “Leadership Vacuum” Deepened?

December 22, 1994

FDA Approves Silicone Gel Breast Implants, Requires 10 Years Of Patient Follow-Up

November 24, 2006